CureGenix Corporation
- Headquarters
- Guangzhou
- Business Model
- B2B
- Last Round
- Series AOct 2016
- Rounds
- 2
About
CureGenix Corporation is a Guangzhou, China-based biopharmaceutical company developing vaccine and immuno-oncology candidates, including proprietary nanoparticle adjuvant technology and PD-1/PD-L1 antibody compositions licensed for combination immunotherapy. The company's research is cited in peer-reviewed vaccine-adjuvant studies and referenced across multiple U.S. patent filings covering programmed death receptor antibody compositions.
Summary
CureGenix Corporation is a Biotech company based in Guangzhou. Its most recent funding was a Series A round in Oct 2016. Investors include F-Prime Capital and Eight Roads Ventures.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2016
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...